IPM Take
The important shift is that MS monitoring may become less dependent on resource-heavy MRI pathways. That could help patients who face travel barriers, waiting times or limited specialist-centre access. But a blood test only becomes useful if health systems define what rising NfL means, when clinicians should repeat testing and when treatment should be reviewed. The access test is not only whether the biomarker is available. It is whether biomarker monitoring changes care early enough to matter.
Executive Summary
On 13 April 2026, Roche announced CE mark approval for the Elecsys Neurofilament Light Chain, NfL, blood test for detecting neuroinflammation in adults diagnosed with relapsing-remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, and is intended to complement routine clinical assessment and MRI rather than replace them. Roche says the test can run on widely available cobas instruments and may support more frequent monitoring of neuroinflammatory activity in people living with RRMS.
Why it matters
- Clinicians: Need guidance on how NfL results should influence monitoring frequency, MRI use, treatment review and escalation decisions.
- Diagnostics / pathology: Must prepare validated workflows, quality control and reporting standards for blood-based neuroinflammation monitoring.
- Payers / public authorities: Should assess whether easier biomarker monitoring improves care efficiency and access, rather than adding cost without clear action rules.
Before this approval, MS monitoring relied heavily on clinical relapses, disability assessment and MRI. Those tools remain essential, but MRI access can be uneven, costly and logistically difficult, especially for patients outside specialist centres.
What has changed is the move toward a standardised blood-based biomarker for neuroaxonal damage. Elecsys NfL measures neurofilament light chain, which reflects nerve cell injury associated with neuroinflammation. Roche positions the test as a tool to complement MRI and clinical assessment, potentially allowing more regular biological monitoring in adults already diagnosed with relapsing-remitting MS.
The eligible population is specific: adults diagnosed with relapsing-remitting MS. This should not be framed as general MS screening or as a standalone diagnostic test. The implementation question is now practical. Laboratories, neurologists and payers need to decide how NfL results fit into routine monitoring, treatment escalation and follow-up.
For IPM, the message is direct: biomarkers can make neurology more personalised only when the care pathway knows how to respond. Without that pathway, the test risks becoming another promising biomarker without clear clinical action.
